Updating of Russian clinical guidelines for chronic heart failure 2024: analysis of key changes

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Presented clinical guidelines of the Russian Society of Cardiology for chronic heart failure (CHF) 2024 have been completed with many innovations that are important for everyday clinical practice. The approach to identifying CHF and influencing its course at early stages is intensified, and understanding of the severe stage of the disease is structured. Concept of optimal drug therapy for all CHF phenotypes is updated, and position of basic drugs for acute CHF decompensation is strengthened. Recommendations for surgical treatment and concomitant diseases are significantly expanded. The article provides an overview of the main updates of 2024 recommendations comparatively to 2020 in order to focus the attention of practicing physicians on modern opportunities and problems in managing patients with CHF.

全文:

受限制的访问

作者简介

Zhanna Kobalava

RUDN University

Email: zkobalava@mail.ru

MD, Dr. Sci. (Medicine), professor, corresponding member of RAS, head of the Department of internal medicine with a course in cardiology and functional diagnostics named after academician V.S. Moiseyev, chief researcher, director of the Institute of clinical medicine, V.V. Vinogradov University Clinical Hospital (branch)

俄罗斯联邦, Moscow

Ivan Nazarov

RUDN University

编辑信件的主要联系方式.
Email: nazarovradomla@mail.ru
ORCID iD: 0000-0002-0950-7487
SPIN 代码: 5954-7828

MD, junior researcher at the Institute of clinical medicine

俄罗斯联邦, Moscow

参考

  1. Терещенко С.Н., Галявич А.С., Ускач Т.М., Агеев Ф.Т., Арутюнов Г.П., Беграмбекова Ю.Л. с соавт. Хроническая сердечная недостаточность. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(11):311–374. [Tereshchenko SN, Galyavich AS, Uskach TM, Ageev FT, Arutyunov GP, Begrambekova YuL et al. 2020 Clinical practice guidelines for Chronic heart failure. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2020;25(11):311–374 (In Russ.)]. EDN: LJGGQV. https://doi.org/10.15829/1560-4071-2020-4083
  2. Галявич А.С., Терещенко С.Н., Ускач Т.М., Агеев Ф.Т., Аронов Д.М., Арутюнов Г.П. с соавт. Хроническая сердечная недостаточность. Клинические рекомендации 2024. Российский кардиологический журнал. 2024;29(11):251–349. [Galyavich AS, Tereshchenko SN, Uskach TM, Ageev FT, Aronov DM, Arutyunov GP et al. 2024 Clinical practice guidelines for chronic heart failure. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2024;29(11):251–349 (In Russ.)]. EDN: WKIDLJ. https://doi.org/10.15829/1560-4071-2024-6162
  3. Canepa M, De Marzo V, Ameri P, Ferrari R, Tavazzi L, Rapezzi C et al. Temporal trends in evidence supporting therapeutic interventions in heart failure and other European Society of Cardiology guidelines. ESC Heart Fail. 2023;10(5):3019–27. PMID: 37550897. PMCID: PMC10567640. https://doi.org/10.1002/ehf2.14459
  4. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M et al.; ESC Scientific Document Group. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–726. PMID: 34447992. https://doi.org/10.1093/eurheartj/ehab368. Erratum in: Eur Heart J. 2021 Dec 21;42(48):4901. https://doi.org/10.1093/eurheartj/ehab670
  5. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022;79(17):e263–e421. PMID: 35379503. https://doi.org/10.1016/j.jacc.2021.12.012
  6. Bozkurt B, Coats AJS, Tsutsui H, Abdelhamid CM, Adamopoulos S, Albert N et al. Universal definition and classification of heart failure: A report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. Eur J Heart Fail. 2021;23(3):352–80. PMID: 33605000. https://doi.org/10.1002/ejhf.2115
  7. Шляхто Е.В. Классификация сердечной недостаточности: фокус на профилактику. Российский кардиологический журнал. 2023;28(1):7–8. [Shlyakhto EV. Classification of heart failure: focus on prevention. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2023;28(1):7–8 (In Russ.)]. EDN: RVHDCY. https://doi.org/10.15829/1560-4071-2023-5351
  8. Kubicius A, Gąsior Z, Haberka M. Heart failure with preserved ejection fraction: Diagnostic value of HFA-PEFF score, H-FPEF score, and the diastolic stress echocardiography. Cardiol J. 2024;31(5):708–15. PMID: 38587116. PMCID: PMC11544415. https://doi.org/10.5603/cj.95191
  9. Przewlocka-Kosmala M, Butler J, Donal E, Ponikowski P, Kosmala W. Prognostic value of the MAGGIC Score, H2FPEF Score, and HFA-PEFF algorithm in patients with exertional dyspnea and the incremental value of exercise echocardiography. J Am Soc Echocardiogr. 2022;35(9):966–75. PMID: 35605894. https://doi.org/10.1016/j.echo.2022.05.006
  10. Ryan M, Petrie MC, Kontopantelis E, Dodd M, Tong G, Marquis-Gravel G et al. Medical therapy and outcomes in REVIVED-BCIS2 and STICHES: An individual patient data analysis. Eur Heart J. 2025;46(22):2052–62. PMID: 40048661. PMCID: PMC12146480. https://doi.org/10.1093/eurheartj/ehaf080
  11. Zannad F, Ferreira JP, Pocock SJ, Anker SD, Butler J, Filippatos G et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: A meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet. 2020;396(10254):819–29. PMID: 32877652. https://doi.org/10.1016/S0140-6736(20)31824-9
  12. Monzo L, Cheema B, Ambrosy AP, Girerd N. Iron repletion in heart failure: A symptomatic win, a survival miss. Heart Fail Rev. 2025;30(5):1127–31. PMID: 40448876. https://doi.org/10.1007/s10741-025-10532-z
  13. Anker SD, Friede T, Butler J, Talha KM, Placzek M, Diek M et al. Intravenous ferric carboxymaltose in heart failure with iron deficiency: The FAIR-HF2 DZHK05 randomized clinical trial. JAMA. 2025;333(22):1965–76. PMID: 40159390. PMCID: PMC11955906. https://doi.org/10.1001/jama.2025.3833
  14. Vaduganathan M, Docherty KF, Claggett BL, Jhund PS, de Boer RA, Hernandez AF et al. SGLT-2 inhibitors in patients with heart failure: A comprehensive meta-analysis of five randomised controlled trials. Lancet. 2022;400(10354):757–67. PMID: 36041474. https://doi.org/10.1016/S0140-6736(22)01429-5
  15. Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381(17):1609–20. PMID: 31475794. https://doi.org/10.1056/NEJMoa1908655
  16. Vaduganathan M, Mentz RJ, Claggett BL, Miao ZM, Kulac IJ, Ward JH et al. Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: A pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF. Eur Heart J. 2023;44(31):2982–93. PMID: 37210743. PMCID: PMC10424880. https://doi.org/10.1093/eurheartj/ehad344
  17. Ono R, Falcao LM. Supra-normal left ventricular function. Am J Cardiol. 2023;207:84–92. PMID: 37734305. https://doi.org/10.1016/j.amjcard.2023.08.169
  18. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M et al. 2023 Focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;44(37):3627–39. PMID: 37622666. https://doi.org/10.1093/eurheartj/ehad195
  19. Sohns C, Fox H, Marrouche NF, Crijns HJGM, Costard-Jaeckle A, Bergau L et al. Catheter ablation in end-stage heart failure with atrial fibrillation. N Engl J Med. 2023;389(15):1380–89. PMID: 37634135. https://doi.org/10.1056/NEJMoa2306037
  20. Merkely B, Hatala R, Wranicz JK, Duray G, Foldesi C, Som Z et al. Upgrade of right ventricular pacing to cardiac resynchronization therapy in heart failure: A randomized trial. Eur Heart J. 2023;44(40):4259–69. PMID: 37632437. PMCID: PMC10590127. https://doi.org/10.1093/eurheartj/ehad591
  21. Baldus S, Doenst T, Pfister R, Gummert J, Kessler M, Boekstegers P et al. Transcatheter repair versus mitral-valve surgery for secondary mitral regurgitation. N Engl J Med. 2024;391(19):1787–98. PMID: 39216093. https://doi.org/10.1056/NEJMoa2408739
  22. Anker SD, Friede T, von Bardeleben RS, Butler J, Khan MS, Diek M et al. Transcatheter valve repair in heart failure with moderate to severe mitral regurgitation. N Engl J Med. 2024;391(19):1799–809. PMID: 39216092. https://doi.org/10.1056/NEJMoa2314328
  23. Yehya A, Lopez J, Sauer AJ, Davis JD, Ibrahim NE, Tung R et al. Revisiting ICD therapy for primary prevention in patients with heart failure and reduced ejection fraction. JACC Heart Fail. 2025;13(1):1–13. PMID: 39641686. https://doi.org/10.1016/j.jchf.2024.09.014
  24. Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C et al.; ESC Scientific Document Group. 2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J. 2023;44(37):3503–626. PMID: 37622657. https://doi.org/10.1093/eurheartj/ehad194
  25. Mebazaa A, Davison B, Chioncel O, Cohen-Solal A, Diaz R, Filippatos G et al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): A multinational, open-label, randomised, trial. Lancet. 2022;400(10367):1938–52. PMID: 36356631. https://doi.org/10.1016/s0140-6736(22)02076-1
  26. Pagnesi M, Metra M, Cohen-Solal A, Edwards C, Adamo M, Tomasoni D et al. Uptitrating treatment after heart failure hospitalization across the spectrum of left ventricular ejection fraction. J Am Coll Cardiol. 2023;81(22):2131–44. PMID: 37257948. https://doi.org/10.1016/j.jacc.2023.03.426
  27. Biegus J, Cotter G, Metra M, Ponikowski P. Decongestion in acute heart failure: Is it time to change diuretic-centred paradigm? Eur J Heart Fail. 2024;26(10):2094–106. PMID: 39169731. https://doi.org/10.1002/ejhf.3423
  28. Badwan OZ, Braghieri L, Skoza W, Agrawal A, Menon V, Tang WHW. When should we consider SGLT-2 inhibitors in patients with acute decompensated heart failure? Cleve Clin J Med. 2024;91(1):47–51. PMID: 38167393. https://doi.org/10.3949/ccjm.91a.23034
  29. Meekers E, Dauw J, Ter Maaten JM, Martens P, Nijst P, Verbrugge FH et al. Urinary sodium analysis: The key to effective diuretic titration? European Journal of Heart Failure expert consensus document. Eur J Heart Fail. 2025;27(6):940–49. PMID: 40017142. https://doi.org/10.1002/ejhf.3632
  30. Meekers E, Martens P, Knevels R, Miseur M, Ezzat A, Croset F et al. Home-based urinary sodium monitoring via point-of-care testing for personalized diuretic titration in heart failure management: The EASY-STOP study. Eur J Heart Fail. 2025;27(6):950–59. PMID: 40389240. https://doi.org/10.1002/ejhf.3693
  31. Jeroen D. Clinical applications of urinary sodium in heart failure from prognostic marker to clinical tool. ESC Heart Fail. 2025. Online ahead of print. PMID: 40557839. https://doi.org/10.1002/ehf2.15350

补充文件

附件文件
动作
1. JATS XML
下载
2. 1. Key randomized clinical trials on chronic heart failure in 2020-2025

下载 (476KB)
索引源数据
3. Fig. 2. Classes and levels of evidence of recommendations on chronic heart failure in 2020 and 2024. The class of indications is the level of reliability of evidence

下载 (99KB)
索引源数据
4. 3. Classes (A) and levels of evidence (B) of recommendations on chronic heart failure in 2020 and 2024 in various sections

下载 (339KB)
索引源数据
5. Примечание: ХСНнФВ - хроническая сердечная недостаточность с низкой фракцией выброса; иАПФ - ингибиторы ангиотензинпре-вращающего фермента; БРА - блокаторы (антагонисты) рецепторов ангиотензина II; АРНИ - ангиотензиновых рецепторов и неприлизи-на ингибитор; ББ - бета-блокатор; АМКР - антагонисты минералокортикоидных рецепторов; иНГЛТ-2 - ингибиторы натрий-глюкозного котранспортера 2-го типа; СН - сердечная недостаточность; ФК - функциональный класс; ФВ ЛЖ - фракция выброса левого желудочка; БОК - класс и уровень доказательности рекомендаций согласно Европейскому обществу кардиологов; ОМТ - оптимальная медикаментозная терапия; СР - синусовый ритм; ЧСС - частота сердечных сокращений.

下载 (430KB)
索引源数据
6. Fig. 5. Recommendations for the treatment of iron deficiency in heart failure

下载 (292KB)
索引源数据
7. Figure 6. Changes in the treatment of chronic heart failure with a moderately reduced and preserved ejection fraction in the clinical recommendations of 2024 compared to 2020.

下载 (334KB)
索引源数据
8. Fig. 7. Recommendations for the treatment of valvular defects in chronic heart failure

下载 (601KB)
索引源数据
9. Figure 8. Recommendations for the prevention of sudden cardiac death and resynchronization therapy

下载 (855KB)
索引源数据

版权所有 © Bionika Media, 2025